Literature DB >> 12813382

Do we still need CK-MB in coronary artery bypass grafting surgery?

D Bimmel1, B Patermann, T Schlosser, K Winkler, K Tiemann, J A Likungu, C J Preusse, A Welz.   

Abstract

AIM: The aim of this study was to evaluate the role of cardiac Troponin I (cTnI) and CK-MB for early prediction of outcome of patients undergoing coronary artery bypass grafting (CABG) surgery.
METHODS: In 134 consecutive patients undergoing CABG-surgery blood samples were analyzed for cTnI concentration and CK-MB activity. ECG, hemodynamic parameters and the need for inotropic support, were continuously registered. Patients were divided into group A (uneventful course), group B (ischemia by ECG, hemodynamic stability) and group C (ischemia by ECG and IABP).
RESULTS: After removal of X-clamp an increase cTnI and CK-MB was observed in all patients. Five hrs after stop of CPB group A (8.3+/-4.2 microg/L) had lower cTnI values compared to group B (14.8+/-5.3 microg/L) (p=0.035) and C (54+/-22.8 microg/L) (p=0.023). The cut off value was 14.8 microg/L. Sensitivity and specificity (99%/97%) was higher for cTnI than for CK-MB (90%/30%). The positive predictive value of outcome was better for cTnI (86%) than for CK-MB (33%).
CONCLUSION: CTnI is a specific and sensitive marker for evaluation of perioperative myocardial ischemia (PMI). Additional determination of CK-MB activity does not provide further clinical information. CTnI should be the marker of first choice in CABG surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813382

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  1 in total

1.  Cardioprotection of Shenfu Injection against myocardial ischemia/reperfusion injury in open heart surgery.

Authors:  Chuan-dong Zheng; Su Min
Journal:  Chin J Integr Med       Date:  2008-06-21       Impact factor: 1.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.